Next 10 |
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced that it has awarded a contract to its contract research organizati...
Amplify Bio to complete GLP study of SPC-15 Novel Intranasal Therapeutic Silo study advances SPC-15 towards first-in-human trial SARASOTA, FL, June 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmen...
Silo Pharma (NASDAQ: SILO) , a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has closed on a previously announced registered direct offering. According to the announcement, ...
Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel for...
SARASOTA, FL, June 06, 2024 (GLOBE NEWSWIRE) -- SARASOTA, FL, June 6, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems...
A look at the top 10 most actives in the United States ENDRA Life Sciences Inc. (NDRA) rose 63.4% to $0.1389 on volume of 479,696,316 shares Nuvve Holding Corp. (NVVE) rose 53.3% to $0.868 on volume of 157,337,871 shares PROSHARES TRUST (SQQQ) fell 6.1% to $9.26 on volume of 149,796,858 s...
A look at the top 10 most actives in the United States ENDRA Life Sciences Inc. (NDRA) rose 88.2% to $0.159999 on volume of 216,555,450 shares Crown Electrokinetics Corp. (CRKN) fell 13.1% to $0.0908 on volume of 52,298,971 shares Actelis Networks Inc (ASNS) rose 591.5% to $3.25 on volume...
2024-06-05 08:54:28 ET More on Silo Pharma Financial information for Silo Pharma Read the full article on Seeking Alpha For further details see: Silo Pharma announces $2 million registered direct offering
SARASOTA, FL, June 05, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic t...
Silo Pharma (NASDAQ: SILO) , a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has submitted a pre-Investigational New Drug (“pre-IND”) briefing package and meet...
News, Short Squeeze, Breakout and More Instantly...
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced that it has awarded a contract to its contract research organizati...
Amplify Bio to complete GLP study of SPC-15 Novel Intranasal Therapeutic Silo study advances SPC-15 towards first-in-human trial SARASOTA, FL, June 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmen...
Silo Pharma (NASDAQ: SILO) , a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has closed on a previously announced registered direct offering. According to the announcement, ...